Actinium-225-labeled HuM195
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Actinium-225-labeled HuM195, covering 2015-02-26 to 2015-02-26. Get the full timeline:
Most recent: Clinical Trial Update: Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies [Phase 1]